Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Neoadjuvant Therapy 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced NSCLC 1

Interventions

Imatinib Mesylate 19Sunitinib 9nilotinib 4ripretinib 3regorafenib 2masitinib 2tanespimycin 1famitinib 1avapritinib 1Sodium Chloride 1Midazolam 1Mastectomy, Segmental 1Immunoglobulin G 1IDRX-42 1Fentanyl 1Disulfides 1Carnitine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × famitinib × Clear all
NCT04409223 2024-02-09

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
185 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡